Your browser doesn't support javascript.
loading
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
Fasching, Peter A; Delea, Thomas E; Lu, Yen-Shen; De Boer, Richard; Hurvitz, Sara A; Moynahan, Aaron; Chandiwana, David; Lanoue, Brad; Hu, Huilin; Thuerigen, Astrid; O'Shaughnessy, Joyce.
Afiliação
  • Fasching PA; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Delea TE; Policy Analysis Inc. (PAI), Brookline, MA, USA.
  • Lu YS; National Taiwan University Hospital, Taipei, Taiwan.
  • De Boer R; Peter MacCallum Cancer Centre, Victoria, Australia.
  • Hurvitz SA; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Moynahan A; Policy Analysis Inc. (PAI), Brookline, MA, USA.
  • Chandiwana D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Lanoue B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Hu H; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Thuerigen A; Novartis Pharma AG, Basel, Switzerland.
  • O'Shaughnessy J; Department of Medical Oncology, Baylor University Medical Center, Texas Oncology and US Oncology Network, Dallas, TX, USA.
Cancer Manag Res ; 13: 8179-8189, 2021.
Article em En | MEDLINE | ID: mdl-34754238
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Cancer Manag Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Cancer Manag Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha